Argus raised the firm’s price target on Cardinal Health (CAH) to $182 from $162 and keeps a Buy rating on the shares. The company issued “robust” fiscal 2026 and long-term growth and capital allocation guidance, the analyst tells investors in a research note. The firm continues to view positively Cardinal Health’s “solid performance” and the expansion of its U.S. production footprint to mitigate any future tariff exposure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health’s Strong Growth Prospects and Enhanced Shareholder Value Drive Buy Rating
- Cardinal Health price target raised to $180 from $170 at BofA
- Cardinal Health price target raised to $181 from $166 at Morgan Stanley
- Cardinal Health price target raised to $170 from $157 at Citi
- Buy Recommendation for Cardinal Health Driven by Strong Financial Outlook and Strategic Initiatives